Regeneron shares slump on worries about Praluent limits; Teva switches M&A law firms on Mylan conflict;

@FiercePharma: GSK, Sanofi hauled up by India's competition watchdog on vaccine tenders. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Mylan recalls more injected cancer drugs it made for Pfizer at its Agila plants in India. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Does brand + generic really add up? Sandoz, Actavis execs count the ways. Article | Follow @CarlyHFierce

> Regeneron ($REGN) shares slumped Wednesday on an FDA panel meeting's vote to approve its anti-cholesterol drug Praluent, developed with Sanofi ($SNY), on worries that the agency will restrict its target population. Report

> Teva Pharmaceutical Industries ($TEVA) switched law firms in its bid to buy fellow generics maker Mylan ($MYL), after a U.S. court recommended against Kirkland & Ellis because it had a pre-existing relationship with Mylan. Report

> One dose of GlaxoSmithKline's ($GSK) human papillomavirus vaccine Cervarix, rather than the currently recommended two, could be enough to prevent the majority of cervical cancers, scientists said. Report

> The National Institute for Health and Care Excellence (NICE) turned down Celgene's ($CELG) Otezla as a treatment for chronic plaque psoriasis on cost-effectiveness grounds. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: HeartWare tells patients how to safely use its blood pump in attempt to overcome slew of recent recalls. Article | Follow @FierceMedDev

@VarunSaxena2: India's Cipla gets first FDA approval of oral pellet to treat HIV/AIDS in infants. FierceDrugDelivery article | Follow @VarunSaxena2

> Biotronik's vascular stent determined effective in challenging cases of peripheral artery disease. Story

> KKR-backed Panasonic Healthcare to buy Bayer diabetes device biz for almost $1.2B. Article

Biotech News

@FierceBiotech: ICYMI: Sanofi and Regeneron's would-be blockbuster clears FDA hurdle, but questions remain. Article | Follow @FierceBiotech

@JohnCFierce: Melinta grabs $67M in pursuit of a big PhIII antibiotics finish, NDA. News | Follow @JohnCFierce

@DamianFierce: This seems to be driving the PCSK9 panelists insane. Item | Follow @DamianFierce

> AstraZeneca R&D chief Briggs Morrison makes an unexpected exit. News

> Merck aces Phase III with knockoffs of Enbrel and Remicade. Article

> SEC: Insider traders lined their pockets on AstraZeneca's $1.3B Ardea deal. Report

Pharma Marketing News

> Merck KGaA's amped-up consumer pitch delivers much-needed sales hike. Story

> Pharma needs some 'marriage counseling' for patient relationships: report. More

> Merck's best hep C strategy is niche marketing, game theory expert figures. Story

> Want new patient relationships? Digital-savvy KOLs could be your intro. Article

> Why sue, FDA asks Amarin: You can spread the word on Vascepa already. Item

Biotech Research News

> CRISPR-Cas9 furor highlights explosive growth of gene editing in China. Report

> Do U.S. biomedical researchers really waste about $28B a year? Story

> Enzyme in mice linked to obesity, diabetes. Item

> NYU study: Blocking receptor protein CXCR4 'decimated' leukemia cells. More

> ALS researchers at Gladstone, Michigan shed new light on a key drug target. Article

Diagnostics News

> Study identifies 16 new genetic variants of Bloom syndrome. News

> U.K. researchers say earlier diagnoses of bladder cancer needed, especially among women. Report

> Health Diagnostic Laboratory rails against physician kickback claims. Story

> Roche receives FDA clearance for test to diagnose herpes using its cobas system. Article

> Exact Sciences joins forces with MD Anderson for lung cancer Dx development. More

And Finally... An Indian woman with drug-resistant tuberculosis who flew in to Chicago in April is now being treated for the disease at the National Institutes of Health in Bethesda, MD. Report

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.